INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China
PR87449
PLYMOUTH MEETING, Pa. and SUZHOU, China, Jan. 4, 2021 /PRNewswire=KYODO JBN/ --
- Partnership Adds Asian Manufacturing Resource to INOVIO's Global
Manufacturing Consortium for INO-4800
- INO-4800 Phase 2 Trial Fully Enrolled in China
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market
precisely designed DNA medicines to treat and protect people from infectious
diseases and cancer, and Advaccine Biopharmaceuticals Suzhou Co., Ltd.
("Advaccine"), an emerging biotech company with next-generation technology in
vaccines, both preventive and therapeutic, today announced that they have
entered into a collaboration and license agreement for COVID-19 DNA vaccine
candidate INO-4800.
Under the collaboration and license agreement, Advaccine will have the
exclusive right to develop, manufacture and commercialize INO-4800 within
Greater China, inclusive of Mainland China, Hong Kong, Macao, and Taiwan.
Advaccine will license its plasmid manufacturing process for use with INO-4800
and other INOVIO pipeline product candidates to INOVIO with the right to
sublicense to INOVIO's manufacturing partners. Additionally, Advaccine will
provide its clinical data to INOVIO in support of INOVIO's global INO-4800
regulatory filings and INOVIO will provide its INO-4800 clinical data for
Advaccine to incorporate into its marketing applications in Greater China.
Advaccine will make to INOVIO an upfront payment of $3.0 million as well as pay
an aggregate of $108.0 million upon the achievement of specified development
and sales-based milestones for INO-4800 in Greater China. INOVIO will be
entitled to receive a royalty equal to a high single-digit percentage of annual
net sales in each region within Greater China.
Dr. J. Joseph Kim, President and Chief Executive Officer of INOVIO, said,
"INOVIO's partnership with Advaccine enables us to leverage their deep
expertise, capabilities and network across the region – making it possible to
rapidly produce and if and when approved, distribute our vaccine candidate to
more people across Greater China. This agreement also provides INOVIO with an
Asian manufacturing partner with a near-term focus on INO-4800 and a long-term
manufacturing resource potentially for other INOVIO products. We are grateful
for Advaccine joining our global manufacturing coalition as a dedicated
resource for Greater China and look forward to our continued partnership in the
fight against COVID-19."
Dr. Bin Wang, Founder and Chairman of Advaccine, said, "We are proud to build
upon our current partnership with INOVIO and join their global manufacturing
consortium. Advaccine will leverage its innovative large-scale DNA plasmid
manufacturing process developed over years -- our GMP manufacturing facility in
Suzhou has the capacity to produce over one hundred million doses of DNA
vaccine per year. Given the strong safety profile and robust immune responses
observed in the U.S. and China clinical trials of INO-4800, we are confident in
the vaccine candidate and are fully committed to the manufacturing of INO-4800
for Greater China. INO-4800 is projected to be stable at room temperature for
over a year, at 37oC for more than a month, and with a five-year projected
shelf life at normal refrigeration temperature. INO-4800 does not need to be
frozen during transport or storage – a critical element when considering the
feasibility of distribution in Greater China and globally."
INOVIO and Advaccine have been working together to advance the clinical
development of INO-4800 in China, having all 640 subjects dosed for the first
vaccination in Phase 2 clinical trial in China. The Phase 2 clinical trial of
INO-4800 in China has enrolled both adults who are 18-59 years old and older
adults (60 years and older) with the primary endpoints of evaluating safety and
immunogenicity within the Chinese population. The dosing regimen involves two
vaccinations at 0 and 28 days with either 1.0 mg or 2.0 mg dosing levels,
similar to the independently run Phase 2 segment of INOVIO's Phase 2/3 clinical
trial for INO-4800 in the U.S, called INNOVATE (INOVIO INO-4800 Vaccine Trial
for Efficacy).
INOVIO also recently announced (
) it has started dosing of subjects in the Phase 2 segment of INNOVATE. For
more information about the INNOVATE clinical trial, see www.clinicaltrials.gov,
identifier NCT04642638.
About the INO-4800 "INNOVATE" Phase 2/3 Clinical Trial
The lead Principal Investigator for INNOVATE is Dr. Pablo Tebas, Professor of
Medicine at the Hospital of the University of Pennsylvania. The Phase 2 segment
of the clinical trial is designed to evaluate safety, tolerability and
immunogenicity of INO-4800 in a 2-dose regimen (1.0 mg or 2.0 mg), in a
three-to-one randomization (in a planned total of 400 subjects) to receive
either INO-4800 or placebo, to confirm the more appropriate dosing level for
each of three age groups (18-50 years, 51-64 years and 65 years and older) for
the subsequent Phase 3 efficacy evaluation. The company strives to ensure
diversity in enrollment, targeting specific populations that are working or
residing in environments with high risk of exposure to SARS-CoV-2, for whom
exposure may be relatively prolonged or for whom personal protective equipment
(PPE) may be inconsistently used, especially in confined settings.
The INNOVATE trial is funded by the U.S. Department of Defense (DoD) Joint
Program Executive Office for Chemical, Biological, Radiological and Nuclear
Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary
of Defense for Health Affairs (OASD (HA)) and the Defense Health Agency (DHA).
In the planned Phase 3 segment of the trial, INOVIO intends to enroll healthy
men and non-pregnant women 18 years and older, to evaluate the efficacy of the
proposed dosing level(s) for each age group based on the data from the Phase 2
evaluation. Participants will be enrolled in a one-to-one randomization to
receive either INO-4800 or a placebo. The Phase 3 segment will be case-driven
with the final number of enrollees to be determined by the incidence of
COVID-19 during the Phase 3 segment. The primary endpoint of the Phase 3
segment will be virologically confirmed COVID-19 disease.
About INOVIO's Global Coalition Advancing INO-4800
INOVIO has assembled a global coalition of collaborators, partners and funders
to rapidly advance the development of INO-4800. To date, the Coalition for
Epidemic Preparedness Innovations (CEPI), the Bill & Melinda Gates Foundation,
and the U.S. Department of Defense have contributed significant funding to the
advancement and manufacturing of INO-4800.R&D collaborators to date include The
Wistar Institute, the University of Pennsylvania, the University of Texas,
Fudan University and Laval University. INOVIO has partnered with Advaccine and
the International Vaccine Institute to conduct clinical trials of INO-4800 in
China and South Korea, respectively. INOVIO is also assessing nonclinical
efficacy of INO-4800 in several animal challenge models with Public Health
England (PHE) and Commonwealth Scientific and Industrial Research Organization
(CSIRO) in Australia. INOVIO is working with a team of contract manufacturers
including Kaneka Eurogentec S.A, Thermo Fisher Scientific, Richter-Helm
BioLogics, and Ology Bioservices to manufacture INO-4800 on a commercial scale
and is seeking additional external funding and partnerships to further scale up
manufacturing capacities to satisfy the urgent global demand for safe and
effective vaccines.
About INO-4800
INO-4800 is INOVIO's DNA vaccine candidate against SARS-CoV-2, the novel
coronavirus that causes COVID-19. INOVIO has extensive experience working with
coronaviruses and was the first company to initiate a Phase 2a trial for
INO-4700, a DNA vaccine candidate for a related coronavirus that causes Middle
East Respiratory Syndrome (MERS).
Composed of an optimized DNA plasmid, INO-4800 is delivered directly into cells
in the body via a proprietary smart device to produce a robust, safe and
tolerable immune response. INO-4800 is the only nucleic-acid based vaccine that
is stable at room temperature for more than a year, at 37o C for more than a
month, has a five-year projected shelf life at normal refrigeration temperature
and does not need to be frozen during transport or storage – all of which are
important considerations when preparing for mass immunizations.
About INOVIO's DNA Medicines Platform
INOVIO has 15 DNA medicine clinical programs currently in development focused
on HPV-associated diseases, cancer, and infectious diseases, including
coronaviruses associated with MERS and COVID-19, being developed under grants
from the Coalition for Epidemic Preparedness Innovations (CEPI) and the U.S.
Department of Defense. DNA medicines are composed of optimized DNA plasmids,
which are small circles of double-stranded DNA that are synthesized or
reorganized by a computer sequencing technology and designed to produce a
specific immune response in the body.
INOVIO's DNA medicines deliver optimized plasmids directly into cells
intramuscularly or intradermally using INOVIO's proprietary hand-held smart
device called CELLECTRA(R). The CELLECTRA(R) device uses a brief electrical
pulse to reversibly open small pores in the cell to allow the plasmids to
enter, overcoming a key limitation of other DNA and other nucleic acid
approaches, such as mRNA. Once inside the cell, the DNA plasmids enable the
cell to produce the targeted antigen. The antigen is processed naturally in the
cell and triggers the desired T cell and antibody-mediated immune responses.
Administration with the CELLECTRA(R) device ensures that the DNA medicine is
efficiently delivered directly into the body's cells, where it can go to work
to drive an immune response. INOVIO's DNA medicines do not interfere with or
change in any way an individual's own DNA. The advantages of INOVIO's DNA
medicine platform are how fast DNA medicines can be designed and manufactured;
the stability of the products, which do not require freezing in storage and
transport; and the robust immune response, safety profile, and tolerability
that have been observed in clinical trials.
With more than 2,000 patients receiving INOVIO investigational DNA medicines in
more than 7,000 applications across a range of clinical trials, INOVIO has a
strong track record of rapidly generating DNA medicine candidates with
potential to meet urgent global health needs.
About Advaccine
Advaccine Biopharmaceuticals Suzhou Co., Ltd. ("Advaccine") is an emerging
clinical stage immunotherapy company pioneering novel preventive and
therapeutic vaccines against infectious diseases, cancers and autoimmune
diseases. Advaccine exploits a wide range of vaccine applications, with
innovative antigen technologies, its adjuvant platform and along with a
cellular immunity assessment platform for the swift development of novel
vaccine and immunotherapeutic candidates. Through years of innovative
preclinical and clinical research, Advaccine has successfully built a broad
portfolio of vaccine candidates including a preventive vaccine based on a novel
adjuvant targeting respiratory syncytial virus (RSV) infection in the elderly
and infants, an immunotherapeutic vaccine against chronic hepatitis B (CHB),
and also immunotherapeutic vaccine candidates against autoimmune diseases and
various cancers. Based on its deep expertise in vaccine research and in-house
large-scale manufacturing capabilities, Advaccine has been able to bring
several vaccine candidates to clinical stages and ready for late stage clinical
testing and commercial launch in the near future.
About INOVIO
INOVIO is a biotechnology company focused on rapidly bringing to market
precisely designed DNA medicines to treat and protect people from infectious
diseases, cancer, and diseases associated with HPV. INOVIO is the first and
only company to have clinically demonstrated that a DNA medicine can be
delivered directly into cells in the body via a proprietary smart device to
produce a robust and tolerable immune response. Specifically, INOVIO's lead
candidate VGX-3100, currently in Phase 3 trials for precancerous cervical
dysplasia, destroyed and cleared high-risk HPV 16 and 18 in a Phase 2b clinical
trial. High-risk HPV is responsible for 70% of cervical cancer, 91% of anal
cancer, and 69% of vulvar cancer. Also in development are programs targeting
HPV-related cancers and a rare HPV-related disease, recurrent respiratory
papillomatosis (RRP); non-HPV-related cancers glioblastoma multiforme (GBM) and
prostate cancer; as well as externally funded infectious disease DNA vaccine
development programs in Zika, Lassa fever, Ebola, HIV, and coronaviruses
associated with MERS and COVID-19 diseases. Partners and collaborators include
Advaccine, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates
Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense
Advanced Research Projects Agency (DARPA)/Joint Program Executive Office for
Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND)/Department
of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute
(IVI), Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National
Cancer Institute, National Institutes of Health, National Institute of Allergy
and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer
Immunotherapy, Plumbline Life Sciences, Regeneron, Richter-Helm BioLogics,
Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army
Institute of Research, and The Wistar Institute. INOVIO also is a proud
recipient of 2020 Women on Boards "W" designation recognizing companies with
more than 20% women on their board of directors. For more information, visit
www.inovio.com.
CONTACTS:
Media: Jeff Richardson, 267-440-4211, jrichardson@inovio.com
Investors: Ben Matone, 484-362-0076, ben.matone@inovio.com
This press release contains certain forward-looking statements relating to our
business, including our plans to develop, manufacture and commercialize DNA
medicines, in particular our vaccine candidate INO-4800 in Greater China in
collaboration with Advaccine, our expectations regarding our research and
development programs, including the planned initiation and conduct of the Phase
2/3 clinical trial of INO-4800 in the United States and a Phase 2 clinical
trial in China, and our ability to successfully manufacture and produce large
quantities of our product candidates if they receive regulatory approval.
Actual events or results may differ from the expectations set forth herein as a
result of a number of factors, including uncertainties inherent in preclinical
studies, clinical trials, product development programs and commercialization
activities and outcomes, our ability to secure sufficient manufacturing
capacity to mass produce our product candidates, the availability of funding to
support continuing research and studies in an effort to prove safety and
efficacy of electroporation technology as a delivery mechanism or develop
viable DNA medicines, our ability to support our pipeline of DNA medicine
products, the ability of our collaborators to attain development and commercial
milestones for products we license and product sales that will enable us to
receive future payments and royalties, the adequacy of our capital resources,
the availability or potential availability of alternative therapies or
treatments for the conditions targeted by us or our collaborators, including
alternatives that may be more efficacious or cost effective than any therapy or
treatment that we and our collaborators hope to develop, issues involving
product liability, issues involving patents and whether they or licenses to
them will provide us with meaningful protection from others using the covered
technologies, whether such proprietary rights are enforceable or defensible or
infringe or allegedly infringe on rights of others or can withstand claims of
invalidity and whether we can finance or devote other significant resources
that may be necessary to prosecute, protect or defend them, the level of
corporate expenditures, assessments of our technology by potential corporate or
other partners or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our Annual
Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report
on Form 10-Q for the quarter ended September 30, 2020 and other filings we make
from time to time with the Securities and Exchange Commission. There can be no
assurance that any product candidate in our pipeline will be successfully
developed, manufactured or commercialized, that final results of clinical
trials will be supportive of regulatory approvals required to market products,
or that any of the forward-looking information provided herein will be proven
accurate. Forward-looking statements speak only as of the date of this release,
and we undertake no obligation to update or revise these statements, except as
may be required by law.
SOURCE INOVIO Pharmaceuticals, Inc.
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。
